Skip to main content
. 2014 Oct 20;124(11):5074–5084. doi: 10.1172/JCI76539

Figure 4. Impact of BRAF and SYK/MEK inhibition on ERK activation in primary CLL cells.

Figure 4

(A–F) Primary CLL cells from multiple patients were highly purified (>97% CD19+CD5+) and exposed to the indicated inhibitors. (A) Representative Western blot analysis for pERK and tERK of the protein lysate at the indicated concentrations of vemurafenib and dabrafenib for patients 1 and 2. The experiment was performed 2 times with similar results. (B) Quantification of the pERK/14-3-3 ratios and pERK/tERK ratios of 10 different patients are displayed (Vem, 1 μM). (C) Addition of the SYK inhibitor R406 decreased the ERK phosphorylation as shown for the protein lysates for patient 3. The experiment was performed 2 times with similar results. (D) Quantification of the pERK/14-3-3 ratios and pERK/tERK ratios of 9 and 5 different patients, respectively, are displayed (Vem, 2.5 μM). (E) Western blot analysis for pERK and tERK of the protein lysate at the indicated concentrations of vemurafenib and trametinib (1 μM) for patient 4. The experiment was performed 3 times with similar results. (F) Quantification of the pERK/tERK ratios and pERK/14-3-3 ratios of all analyzed patients (n = 4) are displayed (Vem, 2.5 μM).